LOS ANGELES, Nov. 15, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2023 Conference on Thursday, November 16th at 1:00 p.m. Eastern Time.
There will be simultaneous and archived webcasts available by clicking here. and at www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.
Details for RadNet's Presentation:
Date: | Thursday, November 16, 2023 |
Time: | 1:00 p.m. Eastern Time |
URL: | https://sidoti.zoom.us/webinar/register/WN_w2qAiY-5QNGhgJt6cXReHw |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$72.25 |
Daily Change: | -0.18 -0.25 |
Daily Volume: | 405,798 |
Market Cap: | US$5.350B |
January 08, 2025 December 04, 2024 December 02, 2024 December 02, 2024 December 01, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load